iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
iTeos Therapeutics reported its Q3 2024 financial results, highlighting key developments such as EMA clearance for a Phase 3 dose of belrestotug and dostarlimab, interim data from inupadenant Phase 2, and the completion of EOS-984 Phase 1 enrollment. The company has a cash balance of $683.9 million, expected to support operations through 2027.
November 12, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iTeos Therapeutics received EMA clearance for a Phase 3 dose of belrestotug and dostarlimab, reported interim data from inupadenant Phase 2, and completed EOS-984 Phase 1 enrollment. The company has a strong cash position to support future milestones.
The EMA clearance for a Phase 3 dose and the completion of EOS-984 Phase 1 enrollment are significant milestones that could positively impact iTeos' stock. The strong cash position further supports the company's ability to achieve future milestones, likely boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100